JP4778954B2 - オピオイド受容体調節薬としての新規な化合物 - Google Patents

オピオイド受容体調節薬としての新規な化合物 Download PDF

Info

Publication number
JP4778954B2
JP4778954B2 JP2007503986A JP2007503986A JP4778954B2 JP 4778954 B2 JP4778954 B2 JP 4778954B2 JP 2007503986 A JP2007503986 A JP 2007503986A JP 2007503986 A JP2007503986 A JP 2007503986A JP 4778954 B2 JP4778954 B2 JP 4778954B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
group
phenyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007503986A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007529527A (ja
JP2007529527A5 (enExample
Inventor
ブレスリン，ヘンリー・ジエイ
カイ，チヤオツオング
ヘー，ウエイ
カバシユ，ロバート・ダブリユー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4778954(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of JP2007529527A publication Critical patent/JP2007529527A/ja
Publication of JP2007529527A5 publication Critical patent/JP2007529527A5/ja
Application granted granted Critical
Publication of JP4778954B2 publication Critical patent/JP4778954B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Eye Examination Apparatus (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Amplifiers (AREA)
  • Amplitude Modulation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2007503986A 2004-03-15 2005-03-14 オピオイド受容体調節薬としての新規な化合物 Expired - Fee Related JP4778954B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55334204P 2004-03-15 2004-03-15
US60/553,342 2004-03-15
PCT/US2005/008339 WO2005090315A1 (en) 2004-03-15 2005-03-14 Novel compounds as opioid receptor modulators

Publications (3)

Publication Number Publication Date
JP2007529527A JP2007529527A (ja) 2007-10-25
JP2007529527A5 JP2007529527A5 (enExample) 2009-01-08
JP4778954B2 true JP4778954B2 (ja) 2011-09-21

Family

ID=34962827

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007503986A Expired - Fee Related JP4778954B2 (ja) 2004-03-15 2005-03-14 オピオイド受容体調節薬としての新規な化合物

Country Status (35)

Country Link
US (8) US7741356B2 (enExample)
EP (5) EP2653465B1 (enExample)
JP (1) JP4778954B2 (enExample)
KR (1) KR101166342B1 (enExample)
CN (2) CN102786476B (enExample)
AR (2) AR048269A1 (enExample)
AT (1) ATE516274T1 (enExample)
AU (1) AU2005224091B2 (enExample)
BR (1) BRPI0508820B8 (enExample)
CA (1) CA2560047C (enExample)
CR (1) CR8655A (enExample)
CY (3) CY1111927T1 (enExample)
DK (5) DK2653465T3 (enExample)
EC (1) ECSP066856A (enExample)
ES (5) ES2596434T3 (enExample)
HR (4) HRP20110694T1 (enExample)
HU (2) HUE029852T2 (enExample)
IL (3) IL178040A (enExample)
LT (2) LT2653465T (enExample)
LU (1) LUC00007I2 (enExample)
ME (3) ME02540B (enExample)
MX (1) MXPA06010642A (enExample)
MY (1) MY146972A (enExample)
NL (1) NL300865I2 (enExample)
NO (3) NO338203B1 (enExample)
NZ (1) NZ549842A (enExample)
PH (1) PH12012501640A1 (enExample)
PL (4) PL2298744T3 (enExample)
PT (4) PT2298744E (enExample)
RS (4) RS52933B (enExample)
SI (4) SI2298744T1 (enExample)
TW (1) TWI361069B (enExample)
UA (1) UA86053C2 (enExample)
WO (1) WO2005090315A1 (enExample)
ZA (1) ZA200608587B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008533143A (ja) * 2005-03-14 2008-08-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ オピオイド調節物質の製造方法
US8344011B2 (en) 2004-03-15 2013-01-01 Janssen Pharmaceutica, N.V. Compounds as opioid receptor modulators

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
JP5420170B2 (ja) 2004-05-14 2014-02-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ カルボキサミド系オピオイド化合物
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
KR20080087817A (ko) 2005-12-14 2008-10-01 브리스톨-마이어스 스큅 컴퍼니 인자 ｘｉａ 억제제로서 아릴프로피온아미드,아릴아크릴아미드, 아릴프로핀아미드 또는 아릴메틸우레아유사체
PT1966130E (pt) 2005-12-23 2014-01-30 Zealand Pharma As Compostos miméticos de lisina modificados
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US20080188545A1 (en) * 2006-12-21 2008-08-07 Alimardanov Asaf R Synthesis of pyrrolidine compounds
EP2176234B1 (en) * 2007-07-09 2016-01-27 Forest Tosara Limited Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
TWI468375B (zh) 2008-10-27 2015-01-11 Janssen Pharmaceutica Nv 製備經保護之ｌ－丙胺酸衍生物之方法
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP5198220B2 (ja) * 2008-11-13 2013-05-15 東ソ−・エフテック株式会社 アミノ酸誘導体の製造方法
US8569348B2 (en) 2009-07-06 2013-10-29 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
EP2524912A1 (en) 2011-05-16 2012-11-21 Bionomics Limited Amine derivatives
EP2709985B1 (en) 2011-05-16 2017-10-04 Bionomics Limited Amine derivatives as potassium channel blockers
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
EP2970133B1 (en) * 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
AU2014236146B2 (en) 2013-03-14 2018-05-17 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
US10702498B2 (en) 2015-07-09 2020-07-07 The Regents Of The University Of California MU opioid receptor modulators
WO2017015606A1 (en) * 2015-07-23 2017-01-26 Teva Pharmaceuticals International Gmbh Solid state forms of eluxadoline
JPWO2017043626A1 (ja) * 2015-09-11 2018-06-21 株式会社カネカ 光学活性４−カルバモイル−２，６−ジメチルフェニルアラニン誘導体の製造法
EP3977994B1 (en) 2015-09-23 2024-04-24 EyePoint Pharmaceuticals, Inc. Activators of tie-2 for use in treating intraocular pressure
CN105250232B (zh) * 2015-09-29 2018-08-14 江苏汇智知识产权服务有限公司 一种伊卢多啉肠溶片及其制备方法
WO2017114446A1 (zh) * 2015-12-31 2017-07-06 苏州晶云药物科技有限公司 艾沙度林的新晶型及其制备方法
EP3272741A1 (en) 2016-07-21 2018-01-24 Euticals S.P.A. New stable solvate crystalline forms of eluxadoline
CN105777584B (zh) * 2016-03-28 2018-01-02 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
CN105693554B (zh) * 2016-04-06 2017-08-08 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
US20190177281A1 (en) * 2016-05-03 2019-06-13 Sromovasam THIRUMALAI RAJAN Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl] [(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino] methyl-2-methoxybenzoic acid and its polymorphs thereof
WO2017208156A1 (en) * 2016-05-30 2017-12-07 Sun Pharmaceutical Industries Limited A process for the preparation of eluxadoline
EP3474847B1 (en) * 2016-06-23 2022-09-07 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018020450A2 (en) 2016-07-28 2018-02-01 Lupin Limited Process for the preparation of eluxadoline
CZ2016548A3 (cs) 2016-09-07 2018-03-14 Zentiva, K.S. Pevné formy eluxadolinu
WO2018047131A1 (en) * 2016-09-09 2018-03-15 Sun Pharmaceutical Industries Limited Amorphous eluxadoline
US10479769B2 (en) 2016-09-20 2019-11-19 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018138272A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline form and process for the preparation thereof
US10738013B2 (en) 2017-01-27 2020-08-11 Quimica Sintetica, S.A. Eluxadoline crystalline forms and processes for their preparation
WO2018202865A1 (en) 2017-05-05 2018-11-08 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
WO2019008604A1 (en) 2017-07-07 2019-01-10 Cipla Limited NEW FORMS OF MU-OPIOID RECEPTOR AGONIST
WO2019144805A1 (zh) * 2018-01-25 2019-08-01 四川科伦博泰生物医药股份有限公司 取代的苯乙胺化合物及其制备方法和用途
WO2019197274A1 (en) 2018-04-09 2019-10-17 Quimica Sintetica, S. A. Process for the preparation of opioid modulators
WO2020039333A1 (en) 2018-08-20 2020-02-27 Allergan Holdings Unlimited Company Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
ES2867895T3 (es) * 2018-11-30 2021-10-21 Phytobiotics Futterzusatzstoffe Gmbh Sistema para el análisis de imágenes de excrementos de animales
CN111377832A (zh) * 2018-12-27 2020-07-07 江苏联昇化学有限公司 一种伊卢多啉中间体制备的新方法
EP3962482A4 (en) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL
WO2021198780A1 (en) 2020-03-30 2021-10-07 Allergan Holdings Unlimited Company Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
IL300110A (en) * 2020-07-28 2023-03-01 Jazz Pharmaceuticals Ireland Ltd Chiral synthesis of RAF inhibitors in compressed cyclics
US11896728B2 (en) 2020-09-29 2024-02-13 Abl Ip Holding Llc Techniques for directing ultraviolet energy towards a moving surface
US11850319B2 (en) 2020-09-29 2023-12-26 Abl Ip Holding Llc Techniques for directing ultraviolet energy towards a moving surface
CN114163348A (zh) * 2020-11-27 2022-03-11 成都泰蓉生物科技有限公司 一种氨酰基取代的l-苯丙氨酸的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD142804A3 (de) * 1977-11-07 1980-07-16 Wagner Guenter Verfahren zur herstellung von na-alkyl-bzw.na-aryl-sulfonylierten omega-amidinophenyl-alpha-aminoalkylcarbonsaeureamiden
US4879398A (en) * 1987-12-31 1989-11-07 Monsanto Company Process for producing 2,6-disubstituted tyrosine
SE9402880D0 (sv) 1994-08-30 1994-08-30 Astra Ab New peptide derivatives
AR003108A1 (es) * 1995-01-27 1998-07-08 Novo Nordisk As Compuestos con propiedades de liberacion de la hormona del crecimiento, composicion farmaceutica que los contienen, el uso de los mismos para la preparación de un medicamento.
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
KR100414321B1 (ko) 1995-04-13 2004-02-18 아벤티스 파마슈티칼스 인크. 타치키닌수용체길항활성을갖는신규한치환된피페라진유도체
WO1997006803A1 (en) 1995-08-21 1997-02-27 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues
AU7710596A (en) 1995-11-29 1997-06-19 Nihon Nohyaku Co., Ltd. Phenylalanine derivatives, optically active substances, salts or coordination compounds thereof, and their use as fungicides
US5792760A (en) 1997-04-23 1998-08-11 Eli Lilly And Company Bisindoles as tachykinin receptor antagonists
IT1304898B1 (it) 1998-09-08 2001-04-05 Menarini Ricerche Spa Prodotti con caratteristiche basiche aventi attivita' antagonista sulrecettore nk-1 e loro impiego in preparazioni farmaceutiche
PT1055665E (pt) * 1999-05-28 2004-03-31 Pfizer Prod Inc Derivados da 3-(3-hidroxifenil)-3-amino-propionamida
FR2796643B1 (fr) 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB0021419D0 (en) 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
US20020072017A1 (en) * 2000-10-19 2002-06-13 Hudnall Phillip Montgomery Stabilized p-phenylenediamine-type photographic color developers in free base form
PL205536B1 (pl) 2000-10-30 2010-04-30 Janssen Pharmaceutica Nv Podstawiona pochodna dihydroindolu, dihydrochinoliny lub dihydroizochinoliny jako inhibitor peptydazy tripeptydowej, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna
EA006507B1 (ru) * 2001-10-15 2005-12-29 Янссен Фармацевтика Н.В. Новые замещенные 4-фенил-4-[1h-имидазол-2-ил] пиперидиновые производные и их применение в качестве селективных непептидных агонистов дельта-опиоидов
US7041681B2 (en) * 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
LT2653465T (lt) 2004-03-15 2016-09-12 Janssen Pharmaceutica Nv Opioidinio receptoriaus moduliatoriai
US7282507B2 (en) 2004-05-03 2007-10-16 Janssen Pharmaceutica N.V. Indole derivatives as selective androgen receptor modulators (SARMS)
WO2006098982A1 (en) * 2005-03-14 2006-09-21 Janssen Pharmaceutica, N.V. Process for the preparation of opioid modulators

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8344011B2 (en) 2004-03-15 2013-01-01 Janssen Pharmaceutica, N.V. Compounds as opioid receptor modulators
US8609709B2 (en) 2004-03-15 2013-12-17 Janssen Pharmaceutica, N. V. Compounds as opioid receptor modulators
US8772325B2 (en) 2004-03-15 2014-07-08 Janssen Pharmaceutica, N.V. Compounds as opioid receptor modulators
US9205076B2 (en) 2004-03-15 2015-12-08 Janssen Pharmaceutica, N.V. Compounds as opioid receptor modulators
US9700542B2 (en) 2004-03-15 2017-07-11 Janssen Pharmaceutica Nv Compounds as opioid receptor modulators
US10213415B2 (en) 2004-03-15 2019-02-26 Janssen Pharmaceutica Nv Compounds as opioid receptor modulators
JP2008533143A (ja) * 2005-03-14 2008-08-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ オピオイド調節物質の製造方法
JP2013234192A (ja) * 2005-03-14 2013-11-21 Janssen Pharmaceutica Nv オピオイド調節物質の製造方法

Also Published As

Publication number Publication date
CN1950342B (zh) 2012-09-26
IL178040A (en) 2013-12-31
IL229444A0 (en) 2013-12-31
US20050203143A1 (en) 2005-09-15
HUE029852T2 (en) 2017-04-28
US7741356B2 (en) 2010-06-22
ES2596434T3 (es) 2017-01-09
EP2298744B1 (en) 2013-06-26
SI2653465T1 (sl) 2016-10-28
KR20060131983A (ko) 2006-12-20
JP2007529527A (ja) 2007-10-25
CY1111927T1 (el) 2015-11-04
US10213415B2 (en) 2019-02-26
PL2653465T3 (pl) 2017-01-31
EP2653465B1 (en) 2016-07-13
HRP20130800T1 (en) 2013-09-30
EP3112352B1 (en) 2018-11-21
MY146972A (en) 2012-10-15
ME02221B (me) 2016-02-20
PT1725537E (pt) 2011-09-08
US20100324051A1 (en) 2010-12-23
US8344011B2 (en) 2013-01-01
US20140256779A1 (en) 2014-09-11
HRP20110694T1 (hr) 2011-12-31
TWI361069B (en) 2012-04-01
US20080096888A1 (en) 2008-04-24
HK1184432A1 (en) 2014-01-24
DK1725537T3 (da) 2011-10-31
SI2298744T1 (sl) 2013-10-30
LTC1725537I2 (lt) 2018-02-26
EP2298744A3 (en) 2011-08-10
HK1105967A1 (en) 2008-02-29
ECSP066856A (es) 2006-11-24
NL300865I1 (nl) 2017-03-14
US20180325870A1 (en) 2018-11-15
SI1725537T1 (sl) 2011-11-30
AR048269A1 (es) 2006-04-12
US9205076B2 (en) 2015-12-08
TW200539876A (en) 2005-12-16
LTPA2017005I1 (lt) 2017-03-27
NO2017007I2 (no) 2017-02-23
ATE516274T1 (de) 2011-07-15
MXPA06010642A (es) 2007-03-26
NZ549842A (en) 2010-10-29
LUC00007I2 (enExample) 2017-05-02
CR8655A (es) 2008-09-09
BRPI0508820A (pt) 2007-08-07
PL1725537T3 (pl) 2011-12-30
EP2298744A2 (en) 2011-03-23
EP2573068B1 (en) 2014-12-31
NO2017007I1 (no) 2017-02-23
BRPI0508820B1 (pt) 2018-04-10
HK1155726A1 (en) 2012-05-25
RS51995B (sr) 2012-04-30
US8609709B2 (en) 2013-12-17
US20140039024A1 (en) 2014-02-06
IL224908A (en) 2015-07-30
RS52933B (sr) 2014-02-28
ME01601B (me) 2014-09-20
PT2573068E (pt) 2015-04-27
US9700542B2 (en) 2017-07-11
ES2533176T3 (es) 2015-04-08
NL300865I2 (nl) 2020-08-17
PH12012501640B1 (en) 2015-10-05
PT2653465T (pt) 2016-09-22
HK1099016A1 (en) 2007-08-03
EP2573068A1 (en) 2013-03-27
CA2560047C (en) 2013-12-24
US20130090478A1 (en) 2013-04-11
HRP20161331T1 (hr) 2016-12-30
US7786158B2 (en) 2010-08-31
RS54199B1 (sr) 2015-12-31
CY1118096T1 (el) 2017-06-28
EP1725537B1 (en) 2011-07-13
ES2428008T3 (es) 2013-11-05
NO20064660L (no) 2006-12-14
ES2705077T3 (es) 2019-03-21
PL2573068T3 (pl) 2015-06-30
DK2653465T3 (da) 2016-08-22
SI2573068T1 (sl) 2015-03-31
EP2653465A1 (en) 2013-10-23
UA86053C2 (ru) 2009-03-25
AU2005224091A1 (en) 2005-09-29
EP2573068B9 (en) 2015-08-26
BRPI0508820B8 (pt) 2022-11-29
WO2005090315A1 (en) 2005-09-29
ME02540B (me) 2017-02-20
HUS1700010I1 (hu) 2017-03-28
DK3112352T3 (en) 2019-01-28
US8772325B2 (en) 2014-07-08
PL2298744T3 (pl) 2013-11-29
NO338203B1 (no) 2016-08-08
NO20160916A1 (no) 2006-12-14
LUC00007I1 (enExample) 2017-03-03
EP3112352A1 (en) 2017-01-04
HRP20150305T1 (hr) 2015-04-24
IL178040A0 (en) 2006-12-31
CN102786476B (zh) 2017-01-18
CA2560047A1 (en) 2005-09-29
CY2017008I2 (el) 2017-11-14
US20160030393A1 (en) 2016-02-04
ES2367576T3 (es) 2011-11-04
AR095848A2 (es) 2015-11-18
KR101166342B1 (ko) 2012-07-18
CN1950342A (zh) 2007-04-18
LT2653465T (lt) 2016-09-12
IL229444A (en) 2017-03-30
PT2298744E (pt) 2013-09-12
ZA200608587B (en) 2008-06-25
RS55122B1 (sr) 2016-12-30
PH12012501640A1 (en) 2015-10-05
EP1725537A1 (en) 2006-11-29
CY2017008I1 (el) 2017-11-14
CN102786476A (zh) 2012-11-21
DK2573068T3 (en) 2015-02-16
DK2298744T3 (da) 2013-09-02
AU2005224091B2 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
JP4778954B2 (ja) オピオイド受容体調節薬としての新規な化合物
AU2016203357B2 (en) Novel compounds as opioid receptor modulators
HK1232866A1 (en) Opioid receptor modulators
HK1232866A (en) Opioid receptor modulators
HK1232866B (en) Opioid receptor modulators
HK1155726B (en) Opioid receptor modulators
HK1099016B (en) Novel compounds as opioid receptor modulators
HK1190391B (en) Opioid receptor modulators
HK1190391A (en) Opioid receptor modulators
AU2012202459A1 (en) Novel compounds as opioid receptor modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071213

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081113

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20101102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110516

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110628

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110704

R150 Certificate of patent or registration of utility model

Ref document number: 4778954

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140708

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees